JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
180.52 USD
+10.43 (+6.13%)
180.51 USD
-0.01 (-0.01%)
JAZZ gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. JAZZ is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year JAZZ was profitable.
JAZZ had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: JAZZ reported negative net income in multiple years.
Each year in the past 5 years JAZZ had a positive operating cash flow.
1.2 Ratios
JAZZ's Return On Assets of -3.24% is fine compared to the rest of the industry. JAZZ outperforms 73.96% of its industry peers.
JAZZ's Return On Equity of -9.31% is fine compared to the rest of the industry. JAZZ outperforms 73.96% of its industry peers.
The Return On Invested Capital of JAZZ (3.95%) is better than 82.81% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for JAZZ is significantly below the industry average of 13.48%.
The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
JAZZ has a Operating Margin of 10.92%. This is amongst the best in the industry. JAZZ outperforms 83.33% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ has a better Gross Margin (88.49%) than 90.63% of its industry peers.
In the last couple of years the Gross Margin of JAZZ has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), JAZZ is destroying value.
JAZZ has less shares outstanding than it did 1 year ago.
JAZZ has more shares outstanding than it did 5 years ago.
The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
JAZZ has an Altman-Z score of 1.55. This is a bad value and indicates that JAZZ is not financially healthy and even has some risk of bankruptcy.
JAZZ has a Altman-Z score of 1.55. This is in the better half of the industry: JAZZ outperforms 61.98% of its industry peers.
The Debt to FCF ratio of JAZZ is 4.33, which is a neutral value as it means it would take JAZZ, 4.33 years of fcf income to pay off all of its debts.
JAZZ's Debt to FCF ratio of 4.33 is amongst the best of the industry. JAZZ outperforms 83.85% of its industry peers.
A Debt/Equity ratio of 1.09 is on the high side and indicates that JAZZ has dependencies on debt financing.
JAZZ has a Debt to Equity ratio of 1.09. This is in the lower half of the industry: JAZZ underperforms 72.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.55 |
ROIC/WACC0.55
WACC7.24%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
JAZZ has a worse Current ratio (1.65) than 67.71% of its industry peers.
A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
The Quick ratio of JAZZ (1.44) is worse than 63.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
Looking at the last year, JAZZ shows a small growth in Revenue. The Revenue has grown by 4.14% in the last year.
The Revenue has been growing by 13.48% on average over the past years. This is quite good.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
JAZZ is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.55% yearly.
Based on estimates for the next years, JAZZ will show a small growth in Revenue. The Revenue will grow by 6.20% on average per year.
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
JAZZ is valuated rather expensively with a Price/Earnings ratio of 22.12.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 80.21% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 25.51. JAZZ is around the same levels.
JAZZ is valuated reasonably with a Price/Forward Earnings ratio of 8.02.
Based on the Price/Forward Earnings ratio, JAZZ is valued cheaper than 91.67% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of JAZZ to the average of the S&P500 Index (34.98), we can say JAZZ is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.12 | ||
| Fwd PE | 8.02 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaply inside the industry as 85.42% of the companies are valued more expensively.
JAZZ's Price/Free Cash Flow ratio is rather cheap when compared to the industry. JAZZ is cheaper than 91.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.84 | ||
| EV/EBITDA | 11.33 |
4.3 Compensation for Growth
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)4.05
EPS Next 2Y3.08%
EPS Next 3Y5.52%
5. Dividend
5.1 Amount
No dividends for JAZZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
180.52
+10.43 (+6.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-3.32%
Ins Owners2.49%
Ins Owner Change0.39%
Market Cap10.95B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts84.8
Price Target193.36 (7.11%)
Short Float %8.7%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.4%
PT rev (3m)1.88%
EPS NQ rev (1m)7.01%
EPS NQ rev (3m)16.08%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)-0.84%
Revenue NQ rev (3m)-0.67%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.12 | ||
| Fwd PE | 8.02 | ||
| P/S | 2.63 | ||
| P/FCF | 8.84 | ||
| P/OCF | 7.87 | ||
| P/B | 2.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.33 |
EPS(TTM)8.16
EY4.52%
EPS(NY)22.52
Fwd EY12.47%
FCF(TTM)20.43
FCFY11.31%
OCF(TTM)22.94
OCFY12.71%
SpS68.54
BVpS65.27
TBVpS-40.13
PEG (NY)N/A
PEG (5Y)4.05
Graham Number109.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.55 |
F-Score5
WACC7.24%
ROIC/WACC0.55
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y7.57%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 6 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Fairly Valued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.64% in the next year.